Preclinical News and Research

RSS

MacroChem acquires Virium Pharmaceuticals

MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.

23 Apr 2008

Discovery of primary driver of tumor development in the stomach

In a discovery that could lead to the development of new treatments for gastric cancer, scientists at the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have discovered what appears to be the primary driver of tumor development in the stomach.

22 Apr 2008

New advance in use of oncolytic viruses as novel cancer treatments

Combining a herpes virus genetically altered to express a drug-enhancing enzyme with a chemotherapy drug effectively and safely reduced the size of highly malignant human sarcoma grafted into mice.

22 Apr 2008

Lorus initiates development program exploring novel route of administration for LOR-2040

Lorus Therapeutics Inc. today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.

22 Apr 2008

MaxCyte introduces large scale transfection technology - accelerates cell-based assay development

MaxCyte has announced the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology.

21 Apr 2008

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Raptor Pharmaceuticals Corp. has announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. , has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.

21 Apr 2008

Aida Pharmaceuticals announces development of new anti-cancer drug

Aida Pharmaceuticals, Inc. has announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer.

18 Apr 2008

New drug for melanoma riluzole shows promise

Rutgers Professor Suzie Chen has found that riluzole, a U.S. Food and Drug Administration (FDA) approved drug used to treat Lou Gehrig's disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.

16 Apr 2008

Drugs in the pipeline: new therapies that could change treatment strategies

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer, according to results from a clinical trial conducted by Boston researchers.

16 Apr 2008

Restricted calorie diets prevent pancreatic inflammation and cancer

Prevention of weight gain with a restricted calorie diet sharply reduced the development of pancreatic lesions that lead to cancer in preclinical research reported today by researchers from The University of Texas at Austin and The University of Texas M. D. Anderson Cancer Center at the American Association for Cancer Research annual meeting.

16 Apr 2008

Promising Australian cancer drug on show in the U.S.

A cancer drug in the process of being developed by two Australian companies has shown promising results in preliminary trials on animals.

16 Apr 2008

Potential treatment for multiple sclerosis goes to trial

A potential treatment for multiple sclerosis (MS), developed by University of Greenwich in association with Kings College, London, has begun clinical trials.

15 Apr 2008

NovoCure presents results from breast cancer pilot study

NovoCure announced today that it presented the results from a single-arm pilot trial evaluating the Novo-TTF, a non-invasive portable medical device, combined with neo-adjuvant chemotherapy for the treatment of patients with locally advanced breast cancer.

15 Apr 2008

Potential new therapy for myeloproliferative disorders

A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia.

8 Apr 2008

Skin product decreases malignant melanoma tumor growth according to study

A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol, produces a pronounced reduction of malignant melanoma cell growth. Dermytol, a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

8 Apr 2008

NanoViricides begins HIV drug animal trials

NanoViricides, Inc. has announced that preliminary animal trials of the Company's HIV therapeutic candidates have begun at a BioSafety Level 3 (BSL-3) Laboratory facility in Boston, MA.

8 Apr 2008

Special journal section explores geriatric assessment

The latest issue of The Journal of Gerontology: Medical Sciences (Vol. 63, No. 3) features a special section devoted to the phenomenon of multidimensional geriatric assessment - an interdisciplinary diagnostic process to determine the medical, psychological, and functional status of at-risk and frail elderly patients in order to develop a coordinated, integrated plan for treatment and long-term follow-up.

7 Apr 2008

FDA approves TREANDA (bendamustine hydrochloride) for chronic lymphocytic leukemia

Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.

7 Apr 2008

Clinical trial to test a novel HIV/AIDS vaccine

This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

4 Apr 2008

Disappointing resuts for pimecrolimus, investigational anti-restenosis drug

A new medication that researchers had hoped would reduce the risk of arterial renarrowing after stenting has turned in a disappointing performance in a multicenter clinical trial, but the multi-reservoir stent that was used to deliver the drug is still considered promising.

1 Apr 2008